Pathstone Holdings’s 10x Genomics TXG Stock Holding History

Pathstone Holdings’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-25,296	Closed	-$537K	–	2417
2026 Q1	$537K	Sell	25,296 -140	-0.6%	-$2.8K	﹤0.01%	1726
2025 Q4	$415K	Sell	25,436 -15,221	-37%	-$230K	﹤0.01%	1817
2025 Q3	$475K	Sell	40,657 -576	-1%	-$7.51K	﹤0.01%	1800
2025 Q2	$477K	Sell	41,233 -2,417	-6%	-$22K	﹤0.01%	1742
2025 Q1	$382K	Buy	43,650 +7,051	+19%	+$88.9K	﹤0.01%	1843
2024 Q4	$526K	Buy	36,599 +13,385	+58%	+$211K	﹤0.01%	1700
2024 Q3	$524K	Buy	23,214 +743	+3%	+$15.4K	﹤0.01%	1706
2024 Q2	$437K	Sell	22,471 -125	-0.6%	-$3.27K	﹤0.01%	1765
2024 Q1	$848K	Buy	22,596 +472	+2%	+$20.7K	﹤0.01%	1380
2023 Q4	$1.24M	Buy	+22,124	New	+$963K	0.01%	955

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Pathstone Holdings's TXG Position: Q2 2026 in Review

Pathstone Holdings sold out of 10x Genomics (TXG) in Q2 2026, closing a stake of 25,296 shares — an estimated $537K sold.

Pathstone Holdings first reported a position in TXG in Q4 2023 and held it in 10 quarters. The position peaked at $1.24M in Q4 2023. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Pathstone Holdings reported no remaining 10x Genomics position as of Q2 2026 after selling out during the quarter.
Pathstone Holdings sold 25,296 10x Genomics shares in Q2 2026, an estimated $537K.
Pathstone Holdings first reported a position in 10x Genomics in Q4 2023 and held it in 10 quarters.
Pathstone Holdings's 10x Genomics position peaked at $1.24M in Q4 2023.
390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.